Noa Lahav

Linking biochemical and cellular efficacy of MERS coronavirus main protease inhibitors

The paper compares three data analysis methods for MERS-CoV MPro inhibitors, finding that modeling the complete concentration-response curve best predicts cellular efficacy.

Crystallographic fragment screening and deep mutational scanning of Zika virus NS2B-NS3 protease enable development of resistance-resilient inhibitors

The paper identifies fragment binders and mutationally intolerant sites in Zika virus NS2B-NS3 protease to develop resistance-resilient antiviral inhibitors.

A Structure-Based Computational Pipeline for Broad-Spectrum Antiviral Discovery

This paper introduces a computational pipeline for identifying broad-spectrum antivirals by analyzing viral sequences, predicting ligand poses, and scoring protein-ligand complexes, validated on SARS-CoV-2 and MERS-CoV datasets.

Discovery of orally bioavailable Zika virus NS2B-NS3 protease inhibitors with efficacy in a murine infection model

The paper identifies orally bioavailable inhibitors of the Zika virus NS2B-NS3 protease that show antiviral activity in vitro and reduce viral RNA load in a murine infection model.

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response

The paper identifies potent nsp3-mac1 inhibitors but finds they do not translate to antiviral activity in cell culture models.